180 Wealth Advisors LLC Acquires 223 Shares of Novo Nordisk A/S (NYSE:NVO)

180 Wealth Advisors LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,549 shares of the company’s stock after buying an additional 223 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $841,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Lockerman Financial Group Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter valued at about $317,000. Chesley Taft & Associates LLC raised its holdings in Novo Nordisk A/S by 2.4% during the 1st quarter. Chesley Taft & Associates LLC now owns 4,245 shares of the company’s stock worth $545,000 after purchasing an additional 100 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Novo Nordisk A/S by 91.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 205,698 shares of the company’s stock worth $26,412,000 after purchasing an additional 98,007 shares during the last quarter. Procyon Advisors LLC raised its holdings in Novo Nordisk A/S by 4.2% during the 1st quarter. Procyon Advisors LLC now owns 57,342 shares of the company’s stock worth $7,363,000 after purchasing an additional 2,316 shares during the last quarter. Finally, Cardinal Capital Management raised its holdings in Novo Nordisk A/S by 2.1% during the 1st quarter. Cardinal Capital Management now owns 68,729 shares of the company’s stock worth $8,887,000 after purchasing an additional 1,422 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 0.6 %

Shares of NVO stock traded up $0.84 on Thursday, reaching $144.51. The company had a trading volume of 2,590,190 shares, compared to its average volume of 4,462,221. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average of $134.16 and a 200-day moving average of $122.88. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $148.15. The stock has a market cap of $648.49 billion, a PE ratio of 49.83, a PEG ratio of 1.46 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The business had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. On average, equities analysts forecast that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on NVO shares. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective for the company. Argus boosted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, June 17th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a research note on Tuesday. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.